Investor profile
Harwood Private Equity LLP
PE
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Harwood Private Equity is a leading investor in the UK lower mid-market, targeting established small and medium-sized UK businesses with enterprise values of between £15 million and £75 million. The firm pursues a low-leverage strategy focused on management buyouts (MBOs), expansion capital, buy-and-build consolidations, and — as a specialist differentiator — public-to-private (PTP) transactions, having completed 26 PTPs since 1999. HPE seeks companies with high-quality operational management, maintainable earnings, decent market share, latent value and significant growth potential that are undervalued or neglected by the broader investor community, across diverse sectors including life sciences, biotechnology, precision manufacturing, multi-site leisure, financial services, media and healthcare. The firm generates returns by creating larger, more profitable businesses through roll-out, acquisition and buy-and-build strategies, and employs a wide range of exit routes including trade sales, IPOs and secondary PE sales.
Notable quotes
“We seek to make a difference by supporting companies with strong potential and high-quality operational management that are undervalued and often neglected by the investor community. We favour low leverage and enjoy exclusive relationships in the market, aiding the acquisition of businesses at attractive entry multiples.”
“We are seven investment professionals with over 160 years of experience of private equity investing and an average of over 30 years in financial services. We can react quickly to opportunities and to execute complex transactions. This gives our private equity funds an advantage in the UK smaller-company space, where company managers and vendors often favour potential acquirers who are decisive, straightforward, experienced and fast moving.”
“HPE6 will seek to invest in profitable companies with strong growth potential, and will include the same public-to-private strategy as its predecessor funds. The investment period will run until 23 December 2030. The Fund currently has c. £110 million of committed capital and remains open to new investors.”
Team
James Agnew
Partner
Jeremy Brade
Partner
Geoffrey Gorman
Partner
Harry Mills
Partner
Timothy Sturm
Partner
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Tissue Regenix Group PLC | Public-to-Private Buyout | — | 2025-12 |
| Frenkel Topping Group plc | Public-to-Private Buyout | — | 2025-09 |
| Crest Foods | Buyout | — | 2024-02 |
| Source BioScience | Public-to-Private Buyout | — | 2022-12 |
| SMT Corporation | Buyout | — | 2022-09 |
| Fothergill's (Mr Fothergill's) | Buyout | — | 2022-02 |
| WaterBox | Buyout | — | 2021-12 |
| APC Technology Group | Public-to-Private Buyout | — | 2019-11 |
| CoventBridge | Buyout | — | 2016-03 |
| 3BL Media | Buyout | — | 2020-12 |
Fit check
Is Harwood Private Equity LLP a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit